Results From The Phase Ii Biomarker Driven Trial With Nivolumab (N) And Ipilimumab Or Vegfr Tyrosine Kinase Inhibitor (Tki) In Naive Metastatic Kidney Cancer (M-Ccrcc) Patients (Pts): The Bionikk Trial
Annals of Oncology(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要